检索范围:
排序: 展示方式:
Taking advantage of drug resistance, a new approach in the war on cancer
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 490-495 doi: 10.1007/s11684-018-0647-7
Identification of the driver mutations in cancer has resulted in the development of a new category of molecularly targeted anti-cancer drugs. However, as was the case with conventional chemotherapies, the effectiveness of these drugs is limited by the emergence of drug-resistant variants. While most cancer therapies are given in combinations that are designed to avoid drug resistance, we discuss here therapeutic approaches that take advantage of the changes in cancer cells that arise upon development of drug resistance. This approach is based on notion that drug resistance comes at a fitness cost to the cancer cell that can be exploited for therapeutic benefit. We discuss the development of sequential drug therapies in which the first therapy is not given with curative intent, but to induce a major new sensitivity that can be targeted with a second drug that selectively targets the acquired vulnerability. This concept of collateral sensitivity has hitherto not been used on a large scale in the clinic and holds great promise for future cancer therapy.
关键词: cancer drug resistance genetic screens senescence targeted therapy
Wenjie Zhu, Binghe Xu
《医学前沿(英文)》 2021年 第15卷 第2期 页码 208-220 doi: 10.1007/s11684-020-0795-4
关键词: endocrine-resistant HR+/HER2- advanced breast cancer randomized clinical trials meta-analysis targeted therapy
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
《医学前沿(英文)》 2021年 第15卷 第2期 页码 221-231 doi: 10.1007/s11684-020-0812-7
关键词: mTOR cancer therapy resistance GSK3 protein degradation E3 ubiquitin ligase PD-L1
Progress and challenges in RET-targeted cancer therapy
《医学前沿(英文)》 2023年 第17卷 第2期 页码 207-219 doi: 10.1007/s11684-023-0985-y
关键词: pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug resistance
null
《医学前沿(英文)》 2015年 第9卷 第2期 页码 134-138 doi: 10.1007/s11684-015-0396-9
Drug resistance is a major factor that limits the efficacy of targeted cancer therapies. In this review, we discuss the main known mechanisms of resistance to receptor tyrosine kinase inhibitors, which are the most prevalent class of targeted therapeutic agent in current clinical use. Here we focus on bypass track resistance, which involves the activation of alternate signaling molecules by tumor cells to bypass inhibition and maintain signaling output, and consider the problems of signaling pathway redundancy and how the activation of different receptor tyrosine kinases translates into intracellular signal transduction in different cancer types. This information is presented in the context of research strategies for the discovery of new targets for pharmacological intervention, with the goal of overcoming resistance in order to improve patient outcomes.
关键词: targeted therapy drug resistance receptor tyrosine kinases cancer
Complex interplay between tumor microenvironment and cancer therapy
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 426-439 doi: 10.1007/s11684-018-0663-7
Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist within and around the tumor mass. The TME is highly dynamic and its importance in different stages of cancer progression has been well recognized. A growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses. TME is significantly remodeled upon cancer therapies, and such change either enhances the responses or induces drug resistance. Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME to improve therapeutic responses are under developing. In this review, we provide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer treatments. We also summarize the strategies that aim to enhance therapeutic efficacy by modulating TME.
关键词: tumor microenvironment therapy response treatment resistance
《医学前沿(英文)》 doi: 10.1007/s11684-023-1050-6
关键词: pancreatic cancer cancer screening single cell molecular alterations precancerous lesion therapy resistance
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
《医学前沿(英文)》 2010年 第4卷 第3期 页码 290-293 doi: 10.1007/s11684-010-0093-7
关键词: breast cancer postmenopausal hormone therapy unopposed estrogen therapy combined estrogen-progestin therapy
Particle therapy for cancers: a new weapon in radiation therapy
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 165-172 doi: 10.1007/s11684-012-0196-4
Particle irradiation started to draw attention in the past decade and has now become a hotspot in the radiation oncology community. This article reviews the most advanced developments in particle irradiation, focusing on the characteristics of proton and carbon ions in radiation physics and radiobiology. The Bragg peak of physical dose distribution causes proton and carbon beams to optimally meet the requirement for cancer irradiation because the Bragg peak permits the accurate concentration of the dose on the tumor, thus sparing the adjacent normal tissues. Moreover, carbon ion has more radiobiological benefits than photon and proton beams. These benefits include stronger sterilization effects on intrinsic radio-resistant tumors and more effective killing of hypoxic, G0, and S phase cells. Compared with the most advanced radiation techniques using photon, such as three-dimensional conformal radiation therapy and intensity-modulated radiation therapy, proton therapy has yielded more promising outcomes in local control and survival for head and neck cancers, prostate carcinoma, and pediatric cancers. Carbon therapy in Japan showed even more promising results than proton therapy. The local controls and overall survivals were as good as that treated by surgery in early stages of non-small cell lung cancer, hepatocellular carcinoma, prostate carcinoma, and head and neck cancers, especially for such highly resistant tumors as melanoma. The non-invasive nature of particle therapy affords more patients with chances to receive and benefit from treatment. Particle therapy is gradually getting attention from the oncology community. However, the cost of particle therapy facilities has limited the worldwide use of this technology.
关键词: radiation therapy particle therapy proton carbon cancer
Passive antibody therapy in emerging infectious diseases
《医学前沿(英文)》 doi: 10.1007/s11684-023-1021-y
关键词: SARS-CoV-2 COVID-19 convalescent plasma hyperimmunoglobulin neutralizing monoclonal antibodies
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao
《医学前沿(英文)》 2019年 第13卷 第4期 页码 427-437 doi: 10.1007/s11684-018-0672-6
关键词: targeted therapy desmoid-type fibromatosis tyrosine kinase inhibitor γ-secretase inhibitor
Prevalence of antifolate drug resistance markers in in China
《医学前沿(英文)》 2022年 第16卷 第1期 页码 83-92 doi: 10.1007/s11684-021-0894-x
关键词: drug resistance antifolates molecular markers Plasmodium vivax China
Metagenomic analysis on resistance genes in water and microplastics from a mariculture system
《环境科学与工程前沿(英文)》 2022年 第16卷 第1期 页码 4-4 doi: 10.1007/s11783-021-1438-y
Microplastics existing widely in different matrices have been regarded as a reservoir for emerging contaminants. Mariculture systems have been observed to host microplastics and antibiotic resistance genes (ARGs). However, more information on proliferation of ARGs and metal resistance genes (MRGs) in mariculture system at the presence of microplastics is needed.
关键词: Antibiotic resistance genes Metal resistance genes Metagenomic analysis Microplastics Mariculture
Hydroxyl radical-involved cancer therapy via Fenton reactions
《化学科学与工程前沿(英文)》 2022年 第16卷 第3期 页码 345-363 doi: 10.1007/s11705-021-2077-3
关键词: hydroxyl radical Fenton catalyst hydrogen peroxide cancer therapy
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 1-10 doi: 10.1007/s11684-020-0741-5
关键词: triple-negative breast cancer immunotherapy targeted therapy
标题 作者 时间 类型 操作
Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor
Wenjie Zhu, Binghe Xu
期刊论文
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
期刊论文
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
null
期刊论文
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges
期刊论文
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
期刊论文
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao
期刊论文